DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Acute myeloid leukemia
Disease landscape & forecast

Personalized treatments create paradigm shift in AML
Acute myeloid leukemia (AML), the most common form of leukemia in adults, has historically been associated with poor five-year overall survival rates. AML is witnessing a paradigm shift from chemotherapy-based treatment toward increasingly targeted and personalized combination therapies. With the uptake of new therapies and combinations, we expect the AML market to grow substantially over the forecast period. Additionally, several drug developers are engaged in the race to launch new therapies in the AML market. The late-phase pipeline is active and spans several drug classes, including reformulations of existing drugs, novel chemotherapies, novel antibody technologies, and small molecules.

What does the future hold for the AML market?

Download the key insights to understand:

  • Current market dynamics
  • Market constraints
  • Current treatment dynamics
  • Unmet needs
  • Emerging pipeline drugs
Key Insights – Acute Myeloid Leukemia
Key questions answered in this report
  • How will second-generation FLT3 inhibitor vie for a share of the FLT3-mutation-positive market?
  • How will Venclexta perform in the sizable and highly lucrative newly diagnosed patient population ineligible for intensive treatment?
  • What will be the uptake of oral azacitidine as a maintenance treatment in AML? How do oncologists view this agent?
  • How do oncologists view Vyxeos, and how will the agent perform in AML?

If you’d like to see these insights for other markets, visit our report store to see our full range

Note – if your company has a DRG subscription you may be able to access this report by logging in, click here.